Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska.
Department of Medicine, Division of Cardiology, Creighton University School of Medicine, Omaha, Nebraska.
Catheter Cardiovasc Interv. 2021 Oct;98(4):638-646. doi: 10.1002/ccd.29313. Epub 2020 Oct 3.
To assess ST elevation myocardial infarction (STEMI) trends and outcomes in nonagenarians undergoing primary percutaneous coronary intervention (pPCI) compared to medical management.
Although nonagenarians (age greater than 90 years) represent the fast-growing age decade of the US population, limited evidence is available regarding trends and outcomes of treatment strategies for STEMI in this population cohort.
We performed a retrospective analysis using the National Inpatient Sample (NIS) database to identify nonagenarians presenting with STEMI and treated with either pPCI or medical management. In-hospital mortality, in-hospital complications, length of stay and in-hospital costs were analyzed.
Between 2010-2017, 41,042 STEMI hospitalizations were identified in nonagenarians, of which 11, 155 (27.2%) included pPCI whereas 29, 887 (72.8%) included medical management. STEMI hospitalizations among nonagenarians decreased over the study period. Overall unadjusted in-hospital mortality was 21.6%, and the hospitalizations that included pPCI had significantly lower mortality compared to the medical management (13.6% vs. 24.5%, p < .001). After adjusting for baseline characteristics, hospitalizations that included pPCI had 42.1% lower odds of in-hospital mortality (adjusted OR: 0.58, 95% CI: 0.50 to 0.67, p < .001). Altogether, in-hospital cardiac, bleeding and vascular complications, length of stay and in-hospital costs were higher in pPCI hospitalizations.
In nonagenarians, STEMI mortality is high, but pPCI is associated with superior outcomes compared to medical management alone. Therefore, pPCI can be considered an acceptable treatment strategy in this population.
评估行直接经皮冠状动脉介入治疗(pPCI)与药物治疗的高龄(>90 岁)ST 段抬高型心肌梗死(STEMI)患者的趋势和结局。
尽管 90 岁以上的高龄人群是美国人口中增长最快的年龄组,但关于该人群 STEMI 治疗策略的趋势和结局,相关证据有限。
我们使用国家住院患者样本(NIS)数据库进行回顾性分析,以确定接受 pPCI 或药物治疗的高龄 STEMI 患者。分析院内死亡率、院内并发症、住院时间和住院费用。
2010 年至 2017 年间,NIS 数据库共确定 41042 例高龄 STEMI 住院患者,其中 1155 例(27.2%)接受 pPCI,29887 例(72.8%)接受药物治疗。研究期间,高龄 STEMI 住院患者人数减少。总体未调整的院内死亡率为 21.6%,接受 pPCI 的住院患者死亡率明显低于接受药物治疗的患者(13.6%比 24.5%,p <.001)。在校正基线特征后,接受 pPCI 的住院患者院内死亡率降低 42.1%(校正比值比:0.58,95%置信区间:0.50 至 0.67,p <.001)。总体而言,pPCI 住院患者的院内心脏、出血和血管并发症、住院时间和住院费用更高。
在高龄人群中,STEMI 死亡率较高,但与单纯药物治疗相比,pPCI 可带来更好的结局。因此,pPCI 可作为该人群的一种可接受的治疗策略。